Pharmaceuticals

Pfizer Secures $6 Billion Licensing Deal for Chinese Cancer Drug SSGJ-707

The agreement grants Pfizer exclusive development and commercialization rights outside China, with a $1.25 billion upfront payment and potential milestone payouts.